Kennen Mackay analyst

Currently out of the existing stock ratings of Kennen Mackay, 140 are a BUY (76.92%), 41 are a HOLD (22.53%), 1 are a SELL (0.55%).

Kennen Mackay

Work Performance Price Targets & Ratings Chart

Analyst Kennen Mackay, has had 65.82% of price targets met with an average potential upside of 31.91%, reached in 345 days on average. Previously, Kennen Mackay worked at RBC, CREDIT SUISSE, CITI.

Kennen Mackay has documented 352 price targets and ratings displayed on 33 stocks. The coverage was on Healthcare, Industrials, Consumer Defensive sectors.

Most recent stock forecast was given on PRTA, Prothena plc at 30-Sep-2024.

Wall Street Analyst Kennen Mackay

Analyst best performing recommendations are on ANAB (ANAPTYSBIO).
The best stock recommendation documented was for ANAB (ANAPTYSBIO) on 4/4/2018. The price target of $57.33 was fulfilled within 2 days with a profit of $5.57 (8.86%), with a performance score of 44.28.

Average potential price target upside

ABEO Abeona Therapeutics AGIO Agios Pharm AIMT Aimmune Therapeutics AKBA Akebia Ther ALXN Alexion Pharmaceuticals ANAB AnaptysBio ARNA Arena Pharmaceuticals ATNX Athenex CLVS Clovis Oncology EXEL Exelixis FPRX Five Prime Therapeutics GMAB Genmab AS IMGN ImmunoGen OBSV ObsEva SA ONCE Spark Therapeutics PBYI Puma Biotechnology PRTA Prothena plc SGEN Seagen XLRN Acceleron Pharma ADCT ADC Therapeutics SA NUVB Nuvation Bio VIRX Viracta Therapeutics FGEN FibroGen RARE Ultragenyx

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 16-Oct-2017

$18

$15.58 (643.80%)

$20

10 days ago
(12-Nov-2026)

0/21 (0%)

$15.71 (686.03%)

Buy Since 08-Nov-2022

$30

$27.58 (1139.67%)

$28

2 months 4 days ago
(18-Sep-2026)

1/8 (12.5%)

$24.43 (438.60%)

1

Buy Since 17-Mar-2026

$21

$18.58 (767.77%)

$22

3 months 8 days ago
(14-Aug-2026)

0/2 (0%)

$15.01 (250.58%)

Buy Since 29-Apr-2025

$17

$14.58 (602.48%)

$19

8 months 5 days ago
(17-Mar-2026)

0/4 (0%)

$12.24 (257.14%)

Buy Since 02-Jun-2025

$22

$19.58 (809.09%)

$20

8 months 13 days ago
(09-Mar-2026)

0/3 (0%)

$16.84 (326.36%)

Show more analysts

Stocks Kennen Mackay covered previously. Scores are shown for active stocks only.

AL Air Lease AMGN Amgen BMRN Biomarin Pharmaceutical CL Colgate-Palmolive Company LIFE aTyr Pharma REGN Regeneron Pharmaceuticals SG Sweetgreen VIR Vir Biotechnology

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?